title: Cystic fibrosis in the era of genomic medicine.
abstract: OBJECTIVE
  The field of cystic fibrosis (CF) is changing dramatically as the scientific knowledge accumulated since the cloning of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is being translated into effective therapies to correct the basic defect and provide better disease models and in-depth understanding of the basic mechanisms of disease.
  
  
  RESULTS
  This review focuses on three main aspects of the recent advances in the field: understanding the lung disease pathophysiology (in particular, the early events that condition its onset), better definition of the complex microbiology of the CF airway, and therapeutic developments. Although the most recently developed therapies, whether approved or under study, do not constitute a definitive cure, the benefit to patients is already becoming clearly apparent.
  
  
  CONCLUSIONS
  As the field continues to change rapidly and new therapies are being identified, CF has become a paradigm for the application of concepts such as translational medicine, genomic medicine, and personalized care, with measurable clinical benefit for the patients affected by this disease.
authors: Department of Pediatrics, Center for Excellence in Pulmonary Biology, Stanford University, 770 Welch Road, Suite 350, Palo Alto, CA 94304, USA. cmilla@stanford.edu
authors: Carlos E
authors: CE
authors: Milla
mesh_terms: D000627:Aminophenols / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy / Q000235:genetics* / Q000382:microbiology / Q000503:physiopathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics; D023281:Genomics / Q000379:methods*; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D015363:Quinolones / Q000627:therapeutic use; D012141:Respiratory Tract Infections / Q000150:complications
chemical_list: D000627:Aminophenols; C505032:CFTR protein, human; D015363:Quinolones; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C545203:ivacaftor